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Introduction {#sec004}
============

Stable coronary artery disease (CAD) is known to have an increased risk of cardiovascular events \[[@pone.0219044.ref001]\]. Several biomarkers such as cardiac troponin, hemoglobin, mean platelet volume, and C-reactive protein (CRP) are reported as predictors of adverse events in stable CAD patients \[[@pone.0219044.ref002]--[@pone.0219044.ref005]\].

Serum albumin (Alb) is the most abundant protein in plasma, representing the main determinant of plasma oncotic pressure and the main modulator of fluid distribution between the body compartments \[[@pone.0219044.ref006]\]. Alb is associated with coronary heart disease \[[@pone.0219044.ref007]\], with possible mechanisms, including responses to inflammation \[[@pone.0219044.ref008]\]. Moreover, the association between low Alb and increased risks of cardiovascular disease and heart failure is reported in several studies \[[@pone.0219044.ref009], [@pone.0219044.ref010]\]. In acute coronary syndrome, low Alb was associated with increased severity of coronary lesions, in-hospital mortality, heart failure, and all-cause death \[[@pone.0219044.ref011]--[@pone.0219044.ref013]\]. A recent study investigated the association between low Alb concentration and adverse cardiovascular events in stable coronary heart disease including old myocardial infarction, previous coronary artery disease, and heart failure \[[@pone.0219044.ref014]\]. However, the prognostic significance of low Alb level at admission in patients with newly diagnosed CAD who underwent percutaneous coronary intervention (PCI) is not well established. Therefore, we aimed to investigate the association between low Alb levels and adverse events in a retrospective cohort of patients with newly diagnosed stable CAD.

Materials and methods {#sec005}
=====================

Study population {#sec006}
----------------

This was a retrospective, single-center cohort study. The cohort included patients admitted to Shinonoi General Hospital between October 2014 and October 2017 for newly diagnosed stable CAD with the exception of old myocardial infarction, treated via elective PCI. Patients with malignancy were excluded. All patients were enrolled after the approval of the Shinonoi General Hospital Ethics Committee, and after written informed consent was obtained. The collected data included clinical characteristics, medical history, major risk factors for CAD, comorbidities, laboratory, electrocardiography, echocardiography, and angiographic data, discharge medications, and post-discharge follow-up findings. All data were fully anonymized before access. The investigation is consistent with the principles outlined in the Declaration of Helsinki.

We measured Alb at admission using the bromocresol purple assay and the LABOSPECT 008 analyzer (Hitachi Ltd, Tokyo, Japan). The measurement range of the Alb assay was 1.0--8.0 g/dL with a coefficient of variation of 5%. The minimum detection limit was 0.1 g/dl.

Definitions and endpoints {#sec007}
-------------------------

Diagnosis of old myocardial infarction was made by the treating clinicians using all available data, including symptoms, laboratory findings, electrocardiograms, echocardiograms, and coronary angiograms. Stable CAD was defined as angiographic evidence of ≥90% epicardial coronary artery stenosis or angiographic evidence of ≥75% epicardial coronary artery stenosis with either a symptom of chest pain induced by exercise or evidence of stress-induced ischemia via any clinical stress-testing modality. Aspirin and thienopyridines were administered before the procedure. Coronary angiography and PCI were performed using standard protocols and guidelines.

Follow-up {#sec008}
---------

The primary outcome was major adverse cardiac events (MACE; defined as all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke) and the secondary outcome was cardiovascular events (CV events; defined as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke). Incidents were validated by chart review.

Statistical analysis {#sec009}
--------------------

Continuous variables are summarized as mean ± standard deviation, if normally distributed and as median \[interquartile range\], if non-normally distributed. Normality was assessed by the Shapiro-Wilk W-test. Comparisons of baseline characteristics were conducted with a contingency table. Pearson's χ ^2^ test was used for categorical variables, the t-test was used for normally distributed continuous variables, and the Wilcoxon or Mann-Whitney test was used for non-normally distributed continuous variables. Spearman's rank correlation method was used as a nonparametric measure of the association between Alb and clinical indices. Patients were then divided into 2 groups according to the median Alb level: the high Alb group (Alb ≥4.0 g/dL, n = 89), and the low Alb group (Alb \<4.0 g/dL, n = 115). Kaplan-Meier survival plots were calculated from baseline to the time of MACE and compared using the log-rank test. Cox proportional-hazards analysis was used to evaluate the independent prognostic utility of Alb. The covariates used were age, sex, body mass index (BMI), hemoglobin, estimated glomerular filtration rate (eGFR), and CRP. Because the study included only a small number of patients, power calculation was performed. In addition, to evaluate the prognostic significance of CRP/Alb ratio in this study, a similar analysis was repeated using the CRP/Alb ratio. A p-value of \<0.05 was considered statistically significant. All statistical analyses were performed using SPSS Statistics for Windows, Version 25 (IBM Corp., Armonk, NY, US).

Results {#sec010}
=======

Study population {#sec011}
----------------

We enrolled 204 patients (mean age, 72 years; male, 69%). The baseline characteristics are shown in [Table 1](#pone.0219044.t001){ref-type="table"}. Patients who developed MACE compared to those who did not were older and had lower Alb (3.5 \[3.0--3.8\] g/dL vs. 4.1 \[3.8--4.4\] g/dL, p \<0.001), hemoglobin, BMI, total cholesterol, and low density lipoprotein cholesterol. CRP and CRP/Alb ratio were higher in patients who developed adverse events than in those who did not. However, no significant correlations were detected between Alb and these clinical indices ([Table 2](#pone.0219044.t002){ref-type="table"}). The baseline lesional characteristics are shown in [Table 3](#pone.0219044.t003){ref-type="table"}.

10.1371/journal.pone.0219044.t001

###### Baseline characteristics.

![](pone.0219044.t001){#pone.0219044.t001g}

  Variable                          Overall Population    MACE                  p-value               
  --------------------------------- --------------------- --------------------- --------------------- ---------
  Age (years)                       72 \[67--79\]         77 \[69--87\]         72 \[65--79\]         0.004
  Male sex, n (%)                   142 (69)              19 (68)               123 (70)              0.828
  BMI                               23.4 \[21.0--25.7\]   21.3 \[18.6--23.3\]   23.8 \[21.4--25.9\]   \<0.001
  Systolic blood pressure (mmHg)    136 \[123--146\]      136 \[124--149\]      137 \[123--147\]      0.878
  Diastolic blood pressure (mmHg)   77 \[71--86\]         77 \[61--90\]         76 \[70--85\]         0.674
  Hypertension, n (%)               151 (74)              21 (75)               130 (74)              0.899
  Dyslipidemia, n (%)               104 (51)              10 (36)               87 (53)               0.082
  Diabetes mellitus, n (%)          73 (36)               8 (40)                65 (37)               0.391
  Atrial fibrillation, n (%)        26 (13)               6 (27)                20 (11)               0.122
  OCI, n (%)                        35 (17)               8 (40)                27 (15)               0.078
  PAD, n (%)                        53 (26)               13 (46)               40 (23)               0.008
  Past smoker, n (%)                101 (49)              9 (32)                92 (52)               0.051
  LVEF (%)                          66 \[63--68\]         67 \[61--68\]         66 \[62--68\]         0.949
  **Medication**                                                                                      
  Aspirin, n (%)                    203 (99)              27 (99)               175 (99)              0.256
  Thienopiridines, n (%)            201 (98)              27 (99)               173 (98)              0.449
  Warfarin, n (%)                   5 (2.4)               2 (7)                 3 (2)                 0.14
  DOAC, n (%)                       21 (10)               4 (14)                17 (10)               0.32
  Statin, n (%)                     111 (54)              12 (43)               99 (56)               0.186
  Ezetimibe, n (%)                  3 (1.5)               0 (0)                 3 (2)                 0.641
  PPI, n (%)                        135 (66)              13 (46)               121 (69)              0.021
  ACE-Is, n (%)                     19 (9)                3 (11)                16 (9)                0.501
  ARBs, n (%)                       88 (43)               14 (50)               74 (42)               0.43
  Beta-blockers, n (%)              55 (27)               6 (21)                49 (28)               0.478
  MRAs, n (%)                       11 (5.4)              2 (7)                 9 (5)                 0.462
  **Laboratory data**                                                                                 
  Hb (g/dL)                         14.1 \[12.1--15.2\]   12.0 \[10.5--14.0\]   14.0 \[12.6--15.2\]   \<0.001
  Alb (g/dL)                        4.0 \[3.6--4.3\]      3.5 \[3.0--3.8\]      4.1 \[3.8--4.4\]      \<0.001
  eGFR (mL/min/1.73m2)              63 \[53--72\]         58 \[35--74\]         65 \[54--76\]         0.127
  AST (U/L)                         23 \[18--29\]         22 \[18--29\]         23 \[18--29\]         0.797
  ALT (U/L)                         18 \[14--26\]         17 \[9--22\]          18 \[14--27\]         0.12
  T-Chol (mg/dL)                    184 \[168--208\]      167 \[140--193\]      186 \[168--209\]      0.014
  HDL-Chol (mg/dL)                  48 \[41--57\]         48 \[38--62\]         49 \[41--57\]         0.54
  LDL-Chol (mg/dL)                  109 \[88--129\]       92 \[76--115\]        110 \[92--131\]       0.015
  Triglycerides (mg/dL)             103 \[76--154\]       93 \[61--181\]        118 \[84--157\]       0.35
  CRP (mg/dL)                       0.09 \[0.04--0.35\]   0.41 \[0.06--1.03\]   0.11 \[0.04--0.25\]   0.004
  CRP/Alb × 100                     2.9 \[1.1--8.9\]      11.8 \[2.7--42.4\]    2.5 \[1.0--7.0\]      0.001
  HbA1c (%)                         5.9 \[5.7--6.4\]      5.9 \[5.5--7.0\]      6.0 \[5.7--6.7\]      0.596

Values are presented as median and interquartile range, or n (%). Abbreviations: ACE-I = angiotensin-converting enzyme inhibitor; Alb = serum albumin; ARB = angiotensin-receptor blocker; BMI = body mass index; CRP = C-reactive protein; DOAC = direct oral anticoagulants; eGFR = estimated glomerular filtration rate; Hb = hemoglobin; HbA1c = hemoglobin A1c; HDL Chol = high-density lipoprotein cholesterol; LDL Chol = low density lipoprotein cholesterol; LVEF = left ventricular ejection fraction; MACE = major adverse cardiac events; MRA = mineralocorticoid receptor antagonist; OCI = old cerebral infarction; PAD = peripheral artery disease; PPI = proton pump inhibitor; T Chol = total cholesterol.

10.1371/journal.pone.0219044.t002

###### Univariate Spearman's rank correlations between serum albumin and clinical indices.
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  Variable               Spearman's Rank   p-value
  ---------------------- ----------------- ---------
  Age (years)            -0.368            \<0.001
  Sex                    0.092             0.191
  BMI                    0.311             \<0.001
  Hb (g/dL)              0.604             \<0.001
  eGFR (ml/min/1.73m2)   0.375             \<0.001
  T Chol (mg/dL)         0.393             \<0.001
  LDL Chol (mg/dL)       0.394             \<0.001
  CRP (mg/dL)            -0.452            \<0.001

Abbreviations as in [Table 1](#pone.0219044.t001){ref-type="table"}.

10.1371/journal.pone.0219044.t003

###### Lesional characteristics.
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                            Overall population   Alb \<4.0 g/dL   Alb ≥4.0 g/dL   p-value
  ------------------------- -------------------- ---------------- --------------- ---------
  Multivessel disease (%)   53 (26)              26 (29)          27 (24)         0.354
  LMT lesions (%)           13 (6)               8 (9)            5 (4)           0.178
  Calcified lesions (%)     29 (14)              20 (23)          9 (8)           0.003
  Ostial lesions (%)        30 (15)              15 (17)          15 (13)         0.446
  Bifurcation lesions (%)   102 (50)             45 (51)          57 (50)         0.888
  CTO lesions (%)           12 (6)               3 (3)            9 (8)           0.18
  DES use (%)               193 (95)             83 (93)          110 (96)        0.453
  BMS use (%)               11 (5)               6 (7)            5 (4)           0.453

Values are presented as median \[interquartile range\], or n (%). Abbreviations: Alb = serum albumin; BMS = bare metal stent; CTO = chronic total occlusion; DES = drug-eluting stent; LMT = left main trunk.

The prognostic impact of serum albumin {#sec012}
--------------------------------------

During a median follow-up of 742 days \[interquartile range: 428--1122\], 28/204 (13.7%) patients experienced MACE (all-cause death, 18; non-fatal myocardial infarction, 3; non-fatal stroke, 11). Low Alb levels were related to an increased risk of MACE (Low Alb group: 24.7% \[22/89\] vs High Alb group: 5.2% \[6/115\], p\<0.001). In Kaplan-Meier analysis, Alb \<4.0 g/dL predicted MACE ([Fig 1](#pone.0219044.g001){ref-type="fig"}). In multivariate Cox proportional hazards analysis, Alb \<4.0 g/dL predicted MACE after adjustment for age, sex, BMI, hemoglobin, eGFR, and CRP ([Table 4](#pone.0219044.t004){ref-type="table"}). After analysis, the power of the study was 98.5%. In the secondary endpoint, 19/204 (9.3%) patients experienced CV events (cardiac death, 6; non-fatal myocardial infarction, 3; non-fatal stroke, 11). In multivariate Cox proportional hazards analysis, Alb \<4.0 g/dL also predicted CV events after adjusting for age (HR 3.344 \[95% CI 1.172--9.545\], p = 0.024), sex (HR 3.879 \[95% CI 1.396--10.781\], p = 0.009), and CRP (HR 3.053 \[95% CI 1.038--8.977\], p = 0.043). Regarding the analysis in CRP/Alb ratio, patients were divided into 2 groups according to the median CRP/Alb ratio level: the high CRP/Alb ratio group (CRP/Alb ratio ≥2.9, n = 98), and the low CRP/Alb ratio group (CRP/Alb ratio \<2.9, n = 98). CRP/Alb ratio also predicted MACE on multivariate Cox proportional hazards analysis after adjusting for age and sex (HR 2.708 \[95% CI 1.134--6.466\], p = 0.025).

![Kaplan-Meier analysis of serum albumin in patients with stable coronary artery disease.\
Low serum albumin (Alb, \<4.0 g/dL) predicted major adverse cardiac events (blue line). Red line, Alb ≥4.0 g/dL.](pone.0219044.g001){#pone.0219044.g001}

10.1371/journal.pone.0219044.t004

###### Multivariable Cox proportional hazards analysis of major adverse cardiac events.
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  Variable               HR (95% CI)             p-value
  ---------------------- ----------------------- ---------
  Albumin adjusted for                           
  Age, Sex               4.128 (1.632--10.440)   0.003
  Age, BMI               3.332 (1.288--8.615)    0.013
  Age, Hb                2.76 (1.033--7.372)     0.043
  Age, eGFR              4.093 (1.595--10.503)   0.003
  Age, CRP               3.373 (1.289--8.828)    0.013

Abbreviations: BMI = body mass index; CI = Confidence interval; CRP = C-reactive protein; eGFR = estimated glomerular filtration rate; Hb = hemoglobin; HR = Hazard ratio.

Discussion {#sec013}
==========

In this study, we identified a significant association between low Alb at admission and MACE in patients hospitalized with newly diagnosed stable CAD. This association was independent of other risk predictors. Previous studies reported an association between low Alb and increased risks of CV events in the general population \[[@pone.0219044.ref009], [@pone.0219044.ref010], [@pone.0219044.ref015]--[@pone.0219044.ref017]\]. Moreover, the prognostic value of low Alb has been reported in acute coronary syndrome and stable coronary heart disease including old myocardial infarction and heart failure \[[@pone.0219044.ref011]--[@pone.0219044.ref014]\]. However, to the best of our knowledge, no prior study has investigated the use of Alb in patients with newly diagnosed stable CAD treated via successful PCI. Although several biomarkers are reported as a predictor of adverse events in stable CAD, risk-stratification tools are still lacking \[[@pone.0219044.ref018]\]. In this study, we demonstrated the prognostic value of Alb in predicting MACE and CV events. Our findings have important clinical implications and suggest that Alb is a useful risk-stratification tool in cases of newly diagnosed stable CAD. Moreover, our study indicates that Alb measurement at admission could identify patients who require aggressive therapy and close outpatient follow-up.

Plasma concentration of albumin is controlled by several processes, including the rate of albumin synthesis, the fractional catabolic rate, albumin distribution between the vascular and extravascular compartments, and exogenous albumin loss \[[@pone.0219044.ref019]--[@pone.0219044.ref021]\]. Low Alb concentration is caused by either the decrease of albumin synthesis, plasma volume expansion, or direct loss of protein from the body. The rate of albumin synthesis is affected by nutritional intake and systemic inflammation \[[@pone.0219044.ref019]\]. In previous studies, which reported the association between low Alb and adverse events in heart failure, inflammation was suggested as the underlying etiology of low Alb \[[@pone.0219044.ref020]\]. Elevated levels of inflammatory mediators, including CRP, have been identified as a predictor of poor prognosis in chronic and acute heart failure, which supports the pathophysiologic theory \[[@pone.0219044.ref022]--[@pone.0219044.ref024]\]. Recent studies have reported the prognostic significance of CRP/Alb ratio in patients with ST elevation myocardial infarction or stable CAD, and suggested that CRP/Alb ratio indicates higher inflammation caused by atherosclerosis \[[@pone.0219044.ref025], [@pone.0219044.ref026]\]. In our study, CRP was significantly higher in patients who developed MACE compared to those who did not, and CRP/Alb ratio independently predicted MACE. Findings from our study suggest that low Alb in stable CAD is caused by systemic inflammation in atherosclerosis. There is evidence that low-grade chronic inflammation and underlying cellular and molecular mechanisms are present in atherosclerosis \[[@pone.0219044.ref027]--[@pone.0219044.ref029]\]. Therefore, it may be possible that patients who develop MACE in stable CAD have more severe atherogenesis-related inflammation. However, this hypothesis is only speculative, and further studies are needed.

Certain treatments that reduce coronary risks, such as dyslipidemia, hypertension, diabetes mellitus, obesity, and smoking limit inflammation \[[@pone.0219044.ref027]\]. Moreover, there is strong evidence that statin therapy can reduce inflammation in atherosclerosis \[[@pone.0219044.ref027], [@pone.0219044.ref030], [@pone.0219044.ref031]\]. Stable CAD patients with low Alb should receive medical tests (e.g. urine analysis or computed tomography) to identify the reason of Alb decrease, and at the same time, receive aggressive therapy to reduce coronary risks. Low density lipoprotein cholesterol should be severely controlled to reduce atherosclerosis. If nutritional intake is lacking, the Nutrition Support Team may support their diet. Interdisciplinary approach should be considered in these patients.

Our study had several limitations. First, we included a small number of patients taken from a single center. Furthermore, the median age of this study was relatively high. The study cohort represents only a limited part of society, and further research involving a large cohort is necessary to verify our findings. Second, only one Alb measurement was available in each case, and serial Alb levels were not evaluated. Third, survival status was ascertained by chart review alone and the median follow-up period was short. Finally, although the transaminase levels were normal, this study did not exclude patients with hepatic failure.

Conclusions {#sec014}
===========

Low Alb was independently associated with adverse clinical events in patients with newly diagnosed stable CAD. Our findings suggest that Alb may be a useful risk-stratification tool in this population. Further studies are needed to identify the mechanism of Alb decrease in these patients.
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